📊 PROK Key Takeaways
Is Prokidney Corp.. (PROK) a Good Investment?
ProKidney is a pre-revenue stage biotech with negative stockholders equity of -$1.0B, indicating technical insolvency despite strong cash position. While revenue growth of +1075% YoY is impressive, the $226K absolute revenue against $44.9M operating losses and -$45.5M free cash flow reveals unsustainable unit economics and an ~2.3-year cash runway at current burn rates.
Prokidney Corp.. Key Strengths (PROK)
- Exceptional revenue growth trajectory (+1075% YoY from biotech development stage
- Strong absolute cash position of $101.9M providing near-term operational runway
- Excellent liquidity ratios (9.06x current/quick) and low debt burden
PROK Stock Risks: Prokidney Corp.. Investment Risks
- Negative stockholders equity of -$1.0B represents fundamental balance sheet insolvency
- Operating cash burn of -$41.7M annually with current revenue of only $226K is not sustainable
- No visible path to profitability; operating margins at -19,881% indicate R&D-heavy pre-commercial stage with execution risk
Key Metrics to Watch
- Quarterly revenue trends and absolute revenue inflection toward sustainability
- Operating cash burn rate and timeline to cash flow breakeven
- Stockholders equity trajectory and recapitalization events or major funding rounds
Prokidney Corp.. (PROK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.06x current ratio provides a solid financial cushion.
PROK Profit Margin, ROE & Profitability Analysis
PROK vs Healthcare Sector: How Prokidney Corp.. Compares
How Prokidney Corp.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prokidney Corp.. Stock Overvalued? PROK Valuation Analysis 2026
Based on fundamental analysis, Prokidney Corp.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prokidney Corp.. Balance Sheet: PROK Debt, Cash & Liquidity
PROK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prokidney Corp..'s revenue has grown significantly by 1,075% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.23 indicates the company is currently unprofitable.
PROK Revenue Growth, EPS Growth & YoY Performance
PROK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $226.0K | -$16.7M | N/A |
| Q3 2025 | N/A | -$16.5M | N/A |
| Q2 2025 | N/A | -$12.5M | N/A |
| Q1 2025 | N/A | -$9.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prokidney Corp.. Dividends, Buybacks & Capital Allocation
PROK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prokidney Corp.. (CIK: 0001850270)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PROK
What is the AI rating for PROK?
Prokidney Corp.. (PROK) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PROK's key strengths?
Claude: Exceptional revenue growth trajectory (+1075% YoY from biotech development stage. Strong absolute cash position of $101.9M providing near-term operational runway.
What are the risks of investing in PROK?
Claude: Negative stockholders equity of -$1.0B represents fundamental balance sheet insolvency. Operating cash burn of -$41.7M annually with current revenue of only $226K is not sustainable.
What is PROK's revenue and growth?
Prokidney Corp.. reported revenue of $226.0K.
Does PROK pay dividends?
Prokidney Corp.. does not currently pay dividends.
Where can I find PROK SEC filings?
Official SEC filings for Prokidney Corp.. (CIK: 0001850270) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PROK's EPS?
Prokidney Corp.. has a diluted EPS of $-0.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PROK's fundamental grade?
Based on our AI fundamental analysis in May 2026, Prokidney Corp.. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PROK stock overvalued or undervalued?
Valuation metrics for PROK: ROE of N/A (sector avg: 15%), net margin of -8,865.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PROK's AI grade for 2026?
Our dual AI analysis gives Prokidney Corp.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PROK's free cash flow?
Prokidney Corp..'s operating cash flow is $-41.7M, with capital expenditures of $3.8M. FCF margin is -20,119.0%.
How does PROK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -8,865.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 9.06 (avg: 2).